Ruxolitinib (Oral Route)


Free

E-newsletter

Subscribe to Housecall

Our weekly general interest
e-newsletter keeps you up to date on a wide variety of health topics.

Sign up now

Ruxolitinib (Oral Route)

Drug Information provided by: Micromedex

US Brand Names

  • Jakafi

Description

Ruxolitinib is used to treat intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. Myelofibrosis is a life-threatening bone marrow problem which is manifested by the following symptoms: enlarged spleen (splenomegaly), severe itching, fever, night sweats, weight loss, bone pain, or unusual tiredness or weakness.

This medicine is available only with your doctor's prescription.

This product is available in the following dosage forms:

  • Tablet
Before Using
DR603559 Portions of this document last updated: July 1, 2012

Source: Drug Information provided by: Micromedex

Copyright © 2013 Thomson Healthcare Inc. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.

Advertisement


Text Size: smaller largerlarger